Scarica l'app Stockscreener
1.25
1.57%
-0.02
Inozyme Pharma Inc Borsa (INZY) Ultime notizie
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025 - The Manila Times
Can This Rare Disease Treatment Transform Young Lives? New ENPP1 Therapy Data Emerges - StockTitan
Inozyme Pharma stock hits 52-week low at $1.32 amid market challenges - MSN
abrdn plc Makes New $472,000 Investment in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma Inc (NASDAQ: INZY) Stock Falling -48.58% Over A Month – Any Room For Its Value To Rise? - Marketing Sentinel
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
INZY Stock: A Comprehensive Analysis and Forecast - The InvestChronicle
Was anything positive for Inozyme Pharma Inc (INZY) stock last session? - US Post News
Upward Trajectory: Inozyme Pharma Inc (INZY) Posts a Slidee, Closing at 1.38 - The Dwinnex
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Rating of “Buy” from Analysts - Defense World
Inozyme Pharma, Inc. (NASDAQ:INZY) Short Interest Update - MarketBeat
Barclays PLC Increases Stock Position in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma (NASDAQ:INZY) Price Target Cut to $30.00 by Analysts at Piper Sandler - Defense World
Inozyme Pharma (NASDAQ:INZY) Price Target Lowered to $11.00 at Wells Fargo & Company - Defense World
Inozyme Pharma (NASDAQ:INZY) Given New $11.00 Price Target at Wells Fargo & Company - MarketBeat
Inozyme shares remain Outperform at Raymond James, target reduced amid study focus - Investing.com Australia
Inozyme shares remain Outperform at Raymond James, target reduced amid study focus By Investing.com - Investing.com South Africa
HC Wainwright Predicts Inozyme Pharma Q1 Earnings - Defense World
Seres Therapeutics Provides Corporate Updates and Financial Results - Defense World
Inozyme Pharma (NASDAQ:INZY) Announces Positive Interim Data and Program Updates**SAN FRANCISCO, Jan 10, 2025 /PRNewswire/ — Inozyme Pharma, Inc. (NASDAQ:INZY) revealed favorable results from its recent interim data analysis and provided - Defense World
HC Wainwright Comments on Inozyme Pharma Q1 Earnings - MarketBeat
Inozyme price target lowered to $11 from $14 at Wells Fargo - MSN
HC Wainwright Forecasts Strong Price Appreciation for Inozyme Pharma (NASDAQ:INZY) Stock - Defense World
Wedbush Reaffirms “Outperform” Rating for Inozyme Pharma (NASDAQ:INZY) - Defense World
Inozyme Pharma stock hits 52-week low at $2.37 amid market challenges - Investing.com Canada
Analyzing Inozyme Pharma (NASDAQ:INZY) & Williston (OTCMKTS:WHCA) - Defense World
Inozyme Pharma Announces Positive Interim Data for INZ-701 - GlobeNewswire
Wedbush Reiterates "Outperform" Rating for Inozyme Pharma (NASDAQ:INZY) - MarketBeat
Inozyme reports promising data on rare disease treatments By Investing.com - Investing.com Canada
Inozyme Pharma (NASDAQ:INZY) Price Target Raised to $16.00 - MarketBeat
Inozyme Pharma stock hits 52-week low at $2.37 amid market challenges By Investing.com - Investing.com South Africa
Inozyme reports promising data on rare disease treatments - Investing.com
Inozyme Pharma Advances with Promising Trial Results - TipRanks
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with - The Bakersfield Californian
Inozyme's INZ-701 Treatment Boosts Infant Survival Rate to 80% in ENPP1 Deficiency Trial - StockTitan
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Barclays PLC Buys 55,497 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Geode Capital Management LLC Boosts Stake in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
State Street Corp Acquires 50,386 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Recommendation of “Buy” by Analysts - Defense World
Inozyme Pharma (NASDAQ:INZY) Coverage Initiated at Raymond James - Defense World
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):